STOCK TITAN
  1. Home
  2. News
  3. LLY

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

News

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) increases quarterly dividend by 15% to $1.30 per share for the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
dividends
-
News

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

Rhea-AI Summary
Eli Lilly and Company (LLY) announced results from the MONARCH 3 clinical trial, showing a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor. The OS outcomes were not statistically significant. Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant (oral SERD) in combination with Verzenio, will be presented at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
-
News

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has announced that Zepbound™ (tirzepatide) injection, indicated for adults with obesity or those who are overweight and have weight-related medical problems, is now available. Following the FDA approval, Zepbound is accessible in six doses through retail and mail-order pharmacies. Zepbound has been added to the National Preferred Formulary for Express Scripts and Cigna Healthcare, with a commercial savings card program available to help eligible individuals access it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
News

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends tender offer to acquire POINT Biopharma Global Inc. (NASDAQ: PNT) for $12.50 per share in cash, without interest. The offer has been extended until Dec. 15, 2023, to satisfy the minimum tender condition. Approximately 24.75% of the issued and outstanding shares have been tendered as of Dec. 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
acquisition
-
News

Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

Rhea-AI Summary
Eli Lilly and Company (LLY) announces the FDA approval of Jaypirca (pirtobrutinib) for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Jaypirca is the first and only non-covalent (reversible) BTK inhibitor, offering a new treatment option for patients with CLL or SLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News

Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024. The new location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies. This will be the company's third Gateway Labs location, with additional sites located in San Francisco and Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
News

Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego

Rhea-AI Summary
Alexandria Real Estate Equities, Inc. (NYSE: ARE) and Eli Lilly and Company (NYSE: LLY) are collaborating to expand Lilly's innovative Gateway Labs model to the San Diego life science cluster, providing emerging biotechnology companies with mission-critical, flexible laboratories and essential, integrated nontechnical space, opportunities to collaborate with Lilly, and access to capital through Lilly and its venture network. The new Gateway Labs site will be located in Alexandria's University Town Center (UTC) submarket, aiming to accelerate the growth of the San Diego cluster's next generation of leading life science companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
partnership
-
News

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) to Invest $2.5 Billion in New High-Tech Manufacturing Site in Germany and $100 Million in Early-Stage Life Sciences Ecosystem
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends the expiration of the tender offer to acquire all outstanding shares of POINT Biopharma Global Inc. (NASDAQ: PNT) at $12.50 per share in cash. The offer, previously set to expire on Nov. 16, 2023, has been extended to Dec. 1, 2023, to satisfy the minimum tender condition. Regulatory approvals have been obtained, and approximately 26.45% of the outstanding shares have been tendered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
acquisition
News

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) obtains NRC Consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license. This follows the completion of Lilly's tender offer to acquire all POINT's common stock for $12.50 per share in cash. The NRC Consent is the final regulatory approval needed for the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
acquisition

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Stock LLY logo
Eli Lilly & Co.

NYSE:LLY

LLY Rankings

#12 Ranked by Market Cap
#1941 Ranked by Dividends

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS